Please ensure Javascript is enabled for purposes of website accessibility

Is It Already Too Late to Buy Nano-X Stock?

By Cory Renauer – Sep 16, 2020 at 6:36AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of the affordable imaging gear maker have more than tripled since its IPO in August.

The coronavirus pandemic has crimped the in-person festivities that come with successful initial public offerings, but it hasn't stopped new healthcare stocks from bursting out of the gates. Shares of Nano-X (NNOX 4.29%) made their public debut on Aug. 21, 2020, and the stock has more than tripled already.

Has the time to buy Nano-X stock already passed? Here's what you need to know about the road ahead of this medical imaging pioneer.

Person in a suit scratching their head.

Image source: Getty Images.

Boosting X-ray availability

In recent decades, images produced by computer tomography (CT) scanners have improved by leaps and bounds. Sadly, replacing one of the X-ray tubes they rely on costs about as much as a modest three-bedroom home in the Midwest.

Worldwide spending on medical imaging equipment and services that use X-ray technology is expected to reach $21 billion next year. Nano-X thinks it can disrupt this massive market with its Nanox.ARC system, a CT scanner that costs far less to manufacture and operate than today's options.

How much less?

Nano-X showed investors a prototype earlier this year of a scanner with a price in the low five-digit range. On average, it costs around $300 to scan a patient with today's X-ray equipment. We don't have all the numbers yet, but it looks like the company's Nanox.ARC scanner can get the job done at a fraction of the cost of today's scanning options.

Nano-X has ambitions that extend far beyond becoming a provider of cheap scanning equipment. The company intends to produce steady cash flows with a pay-per-scan pricing structure. Without a major investment required to bring a CT scanner into their facilities, heaps of small healthcare providers could become this company's regular customers.

Earlier this month, Nano-X entered an agreement with SPI Medical, a medical device distributor in Mexico, to deploy 630 Nanox Systems. If Nanox.ARC earns regulatory approval and passes an acceptance test, SPI Medical will pay Nano-X a minimum annual service fee of $17 million for seven years.

Maybe it's still too soon

At recent prices, Nano-X boasts a $1.6 billion market cap, which doesn't seem unreasonable for a company that could become the world's largest provider of scanning equipment and ancillary services over the next few years. That is, until you consider the apparent risks.

Before throwing everything you've got at what looks like a terrific opportunity on the surface, it's important to understand that Nano-X is still a development-stage business. The company produced a working prototype earlier this year, but still hasn't proven it can manufacture its scanners at scale.

The most troubling thing about a Nano-X investment at the moment, though, is its lack of regulatory clearance. In January, the company submitted an application to a third-party reviewer for a single-source version of the Nanox.ARC scanner. Instead of forwarding the application to the Food and Drug Administration, though, the reviewer sent it back to Nano-X in March with a major deficiency letter attached.

Doctor with cash in the breast pocket of their lab coat.

Image source: Getty Images.

Now what?

Nano-X lost $13.8 million during the first six months of 2020, and it's going to lose a lot more before it has a chance to generate steady revenue in the U.S. The third-party reviewer Nano-X hired assumes the FDA will want the company to address deficiencies in its initial application, including performance test results that the company still hasn't delivered. 

Nano-X has conducted additional product testing and expects to submit the results to its third-party reviewer by the end of September. The company also plans to submit an application for a multiple-source Nanox.ARC before the end of the year. It's the multiple-source version the company intends to commercialize at scale. 

If the market gets the impression that the deficiencies in Nanox-ARC's first application package were more significant than the company has let on, this stock will fall hard. Investors probably want to wait until this risky start-up proves it can develop, market, and manufacture a product at scale.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nano-X Imaging Ltd. Stock Quote
Nano-X Imaging Ltd.
$11.91 (4.29%) $0.49

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.